- Size
- 10mg
- Purity
- 99.64%
- Formula
- C50H69N15O9
Melanotan 2 (MT-II) is a synthetic cyclic lactam analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), designed at the University of Arizona using molecular-dynamics modelling of the native hormone's bioactive conformation. Cyclisation and the D-phenylalanine substitution at position 7 give the molecule far greater potency and metabolic stability than linear alpha-MSH, which is degraded within minutes in circulation.
Pharmacologically, MT-II is a non-selective melanocortin-receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. MC1R signalling on melanocytes activates adenylate cyclase, raising cAMP and driving the tyrosinase-dependent eumelanin synthesis pathway; MC3R and MC4R are expressed centrally and account for the appetite and autonomic effects reported in the clinical literature. This receptor promiscuity is why MT-II became a reference tool compound for dissecting melanocortin biology, and why later clinical candidates pursued receptor-selective analogues instead.
Human data are limited to small early-phase studies: a pilot phase-I trial characterised tolerability and melanotropic activity of subcutaneous MT-II under bodyweight-based dosing, and a double-blind crossover study documented its MC4R-mediated erectile effects — the observation that led to the development of the selective analogue bremelanotide (PT-141). MT-II itself remains an unapproved research compound.
Categorised as Skin — Copper peptides and compounds for dermal research.For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.